Factors Associated with Access to Immunotherapy and Its Impact on Survival in Mucosal Melanoma

Joanne Jee Yeon Lee; Donovan Kearns; Medora Rodrigues; Blake Babcock; Naveenraj L Solomon; Maheswari Senthil; Mark E Reeves; Carlos A Garberoglio; Jukes P Namm

Factors Associated with Access to Immunotherapy and Its Impact on Survival in Mucosal Melanoma

Joanne Jee Yeon Lee, Donovan Kearns, Medora Rodrigues, Blake Babcock, Naveenraj L Solomon, Maheswari Senthil, Mark E Reeves, Carlos A Garberoglio, Jukes P Namm

Research output: Contribution to journal › Article › peer-review

Abstract

Mucosal melanoma is rare, comprising only 1.4% of all melanomas in the United States. Yet it is associated with a worse prognosis compared to cutaneous melanoma due to aggressive biology and advanced stage at diagnosis with a reported 5-year survival rate of less than 30%. Although there are no established guidelines for the treatment of mucosal melanoma, immunotherapy has been increasingly used for the management of advanced mucosal melanoma.

Original language	American English
Journal	Default journal
State	Published - 1800

Access to Document

Factors Associated with Access to Immunotherapy and Its Impact onFinal published version, 174 KBLicense: CC BY

OpenUrl availability

Full text

Cite this

@article{d68b2b270f4f40a2856dde14aa7f247a,

title = "Factors Associated with Access to Immunotherapy and Its Impact on Survival in Mucosal Melanoma",

abstract = " Mucosal melanoma is rare, comprising only 1.4% of all melanomas in the United States. Yet it is associated with a worse prognosis compared to cutaneous melanoma due to aggressive biology and advanced stage at diagnosis with a reported 5-year survival rate of less than 30%. Although there are no established guidelines for the treatment of mucosal melanoma, immunotherapy has been increasingly used for the management of advanced mucosal melanoma.",

author = "Lee, {Joanne Jee Yeon} and Donovan Kearns and Medora Rodrigues and Blake Babcock and Solomon, {Naveenraj L} and Maheswari Senthil and Reeves, {Mark E} and Garberoglio, {Carlos A} and Namm, {Jukes P}",

year = "1800",

language = "American English",

journal = "Default journal",

}

TY - JOUR

T1 - Factors Associated with Access to Immunotherapy and Its Impact on Survival in Mucosal Melanoma

AU - Lee, Joanne Jee Yeon

AU - Kearns, Donovan

AU - Rodrigues, Medora

AU - Babcock, Blake

AU - Solomon, Naveenraj L

AU - Senthil, Maheswari

AU - Reeves, Mark E

AU - Garberoglio, Carlos A

AU - Namm, Jukes P

PY - 1800

Y1 - 1800

N2 - Mucosal melanoma is rare, comprising only 1.4% of all melanomas in the United States. Yet it is associated with a worse prognosis compared to cutaneous melanoma due to aggressive biology and advanced stage at diagnosis with a reported 5-year survival rate of less than 30%. Although there are no established guidelines for the treatment of mucosal melanoma, immunotherapy has been increasingly used for the management of advanced mucosal melanoma.

AB - Mucosal melanoma is rare, comprising only 1.4% of all melanomas in the United States. Yet it is associated with a worse prognosis compared to cutaneous melanoma due to aggressive biology and advanced stage at diagnosis with a reported 5-year survival rate of less than 30%. Although there are no established guidelines for the treatment of mucosal melanoma, immunotherapy has been increasingly used for the management of advanced mucosal melanoma.

UR - https://scholarsrepository.llu.edu/llu-student-journal/vol3/iss1/6

M3 - Article

JO - Default journal

JF - Default journal

ER -

Factors Associated with Access to Immunotherapy and Its Impact on Survival in Mucosal Melanoma

Abstract

Access to Document

OpenUrl availability

Other files and links

Cite this